Capricor Therapeutics, Inc.
NASDAQ:CAPR · NASDAQ Global Select
-$0.14 today
Vol 3.06M · Avg 1.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CAPR · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$114.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.32, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 -100.0% | $22.3M -11.5% | $25.2M +886.8% | $2.6M +941.8% | $244.9K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $50.0M +37.1% | $36.4M +67.1% | $21.8M | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 +100.0% | -$27.7M -145.8% | -$11.3M +41.5% | -$19.3M -7966.7% | $244.9K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | -124.4% -79.6pp | -44.8% +710.3pp | -755.1% -855.1pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $84.5M +69.0% | $50.0M +37.1% | $36.4M +67.1% | $21.8M +60.8% | $13.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $22.7M +53.0% | $14.9M +16.1% | $12.8M +22.8% | $10.4M +37.0% | $7.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $108.1M +627.4% | $14.9M +16.1% | $12.8M +22.8% | $10.4M -50.8% | $21.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.9M +32.5% | $1.4M +33.3% | $1.1M +100.5% | $533.1K +117.0% | $245.7K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$100.1M -156.4% | -$39.0M -84.0% | -$21.2M +25.5% | -$28.5M -44.0% | -$19.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | -175.3% -91.0pp | -84.3% +1032.2pp | -1116.5% +6959.1pp | -8075.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$108.1M -154.1% | -$42.6M -76.8% | -$24.1M +18.9% | -$29.7M -41.8% | -$20.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | -191.1% -95.5pp | -95.6% +1068.3pp | -1163.9% +7385.9pp | -8549.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.3M +184.1% | $2.2M +27.4% | $1.7M +231.5% | $521.5K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.0M | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $3.1M +47.7% | $2.1M +17.2% | $1.8M +164.1% | $677.9K -26.0% | $915.9K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$105.0M -159.6% | -$40.5M -81.6% | -$22.3M +23.2% | -$29.0M -44.9% | -$20.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | -181.7% -93.2pp | -88.5% +1048.8pp | -1137.4% +7038.5pp | -8175.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$105.0M -159.6% | -$40.5M -81.6% | -$22.3M +23.2% | -$29.0M -44.9% | -$20.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | -181.7% -93.2pp | -88.5% +1048.8pp | -1137.4% +7038.5pp | -8175.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -96.5% | -$1 -38.6% | -$1 +29.7% | -$1 -35.6% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -96.5% | -$1 -38.6% | -$1 +29.7% | -$1 -35.6% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $46.5M +32.0% | $35.2M +31.5% | $26.8M +9.1% | $24.6M +6.3% | $23.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $46.5M +32.0% | $35.2M +31.5% | $26.8M +9.1% | $24.6M +6.3% | $23.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$503.54M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$481.64M
Cabaletta Bio, Inc.
NASDAQ:CABA
$468.78M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$389.86M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$345.48M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$263.20M
Editas Medicine, Inc.
NASDAQ:EDIT
$252.09M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$210.47M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$190.70M
Immutep Limited
NASDAQ:IMMP
$55.49M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CAPR generate?
Capricor Therapeutics, Inc. (CAPR) reported $0.00 of revenue in fiscal 2025.
Is CAPR profitable?
Capricor Therapeutics, Inc. (CAPR) reported -$105,043,946.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.